相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
Ian Krop et al.
CLINICAL CANCER RESEARCH (2014)
Imaging EGFR and HER2 by PET and SPECT: A Review
Emily B. Corcoran et al.
MEDICINAL RESEARCH REVIEWS (2014)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer
Jolien Heukelom et al.
BMC CANCER (2013)
Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma
Hye Jin Kang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Marlous Arjaans et al.
CANCER RESEARCH (2013)
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
Marcin Okroj et al.
CANCER TREATMENT REVIEWS (2013)
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
S. Heskamp et al.
CURRENT MOLECULAR MEDICINE (2013)
Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma
Alexander B. Stillebroer et al.
EUROPEAN UROLOGY (2013)
Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
Sandra Heskamp et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Expression and clinical relevance of MET and ALK in Ewing sarcomas
Emmy D. G. Fleuren et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas
Flavio Forrer et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
89Zr- Bevacizumab PET Imaging in Primary Breast Cancer
Sietske B. M. Gaykema et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Kenji Tamura et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients
A. C. M. van de Luijtgaarden et al.
TARGETED ONCOLOGY (2013)
HER2 therapies and gastric cancer: A step forward
Ramon Andrade de Mello et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
Michael Pollak
CLINICAL CANCER RESEARCH (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities
Michele De Palma et al.
MOLECULAR ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?
Joseph G. Jurcic
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Targeting IGF-1R: throwing out the baby with the bathwater?
B. Basu et al.
BRITISH JOURNAL OF CANCER (2011)
Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507
Emmy D. G. Fleuren et al.
CLINICAL CANCER RESEARCH (2011)
VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients
Wouter B. Nagengast et al.
EUROPEAN JOURNAL OF CANCER (2011)
Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival
Katia Scotlandi et al.
EUROPEAN JOURNAL OF CANCER (2011)
Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model
Bianca A. W. Hoeben et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250
Daniel A. Pryma et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
Daniel V. T. Catenacci et al.
CANCER DISCOVERY (2011)
In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
Neelesh Sharma et al.
Therapeutic Advances in Medical Oncology (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
Ingrid M. E. Desar et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation
Takumi Sugimoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET
Hugo J. W. L. Aerts et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts
Kristin McLarty et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Radioisotopic Localization of (90)Yttrium-Ibritumomab Tiuxetan in Patients with CD20+Non-Hodgkin's Lymphoma
S. A. Jacobs et al.
MOLECULAR IMAGING AND BIOLOGY (2009)
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma
Sofiane Maza et al.
NEURO-ONCOLOGY (2009)
Systematic Review of HER2 Breast Cancer Testing
Marta Cuadros et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2009)
Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression
Marian G. W. Scheer et al.
EUROPEAN JOURNAL OF CANCER (2008)
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30
Lars R. Perk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Implications of EGFR PharmDX (TM) Kit for cetuximab eligibility
Christian Ensinger et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2008)
Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2006)
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma
Michael F. Leahy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Patrick J. Perik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
MJ Morris et al.
CLINICAL CANCER RESEARCH (2005)
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies:: Effect of multiple treatments on myelotoxicity
S Vallabhajosula et al.
CLINICAL CANCER RESEARCH (2005)
Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma
AH Brouwers et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy
AS Gokhale et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma
JA Boucek et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Imaging of central nervous system lymphomas with iodine-123 labeled rituximab
M Dietlein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High interstitial fluid pressure -: An obstacle in cancer therapy
CH Heldin et al.
NATURE REVIEWS CANCER (2004)
Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections
D Atkins et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma:: A phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital
JH Turner et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
